Reuters logo
BRIEF-Aerie Pharmaceuticals initiates Mercury 3 clinical trial of Roclatantm 0.02 pct/0.005 pct
September 6, 2017 / 11:04 AM / 19 days ago

BRIEF-Aerie Pharmaceuticals initiates Mercury 3 clinical trial of Roclatantm 0.02 pct/0.005 pct

Sept 6 (Reuters) - Aerie Pharmaceuticals Inc

* Aerie Pharmaceuticals initiates Mercury 3 clinical trial of Roclatantm (netarsudil/latanoprost ophthalmic solution) 0.02 percent/0.005 percent

* Aerie Pharmaceuticals Inc - currently expect to read out topline 90-day efficacy data for trial by early 2019​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below